National Project Implementation Plan - NVBDCP

Chapter 7
Policy and Strategy Development, Capacity Building and Monitoring
and Evaluation
7.1 Project Component 3: Policy and Strategy
Development, Capacity Building and Monitoring and Evaluation [Rs.
2084 million]
Component 3 is a cross cutting area. It would be covering both malaria
control and Kala-azar elimination and will include three sub-components:
Sub-Component 3.a: Policy and Strategy Development [Rs. 924
million]
Sub-Component 3.b: Program Management and Capacity Building
[Rs. 968 million]
Sub-Component 3.c: Monitoring and Evaluation [Rs. 192 million]
7.1.1 Sub-Component 3.a: Policy and Strategy Development
The Directorate of the NVBDCP is primarily responsible for policy
development and strategic planning. To facilitate these tasks, the project
would complement the ongoing technical assistance from GFATM with
appropriate consultant support in the areas of procurement, financial
management, M&E, Information technology, vulnerable community plan and
environmental safety. Activities organized by the unit would include the
updating of evidence-based policies for prevention, diagnosis and treatment
of malaria and elimination of Kala-azar and translation of these policies to
operational guidelines training materials and courses; quality assurance,
operational research & evaluation of different delivery models in the private
and public sectors, Impact evaluation for malaria control, periodic external
reviews of the program; monitoring of drug resistance and insecticide
effectiveness; assessment of quality of medicines and the promotion and
establishment of public-private partnerships for the distribution of longlasting
insecticidal nets.
NVBDC will update and strengthen monitoring of therapeutic efficacy of
antimalarial and anti Kala-azar medicines, insecticide resistance and quality
of medicines to contain the problems of drug and insecticide resistance and
ensure their efficacy. This will be done through monitoring of therapeutic
efficacy of SP and ACTs so that effective drugs are used in the treatment of
malaria. Similiarly, therapeutic efficacy of new first line anti Kala-azar
medicines will be monitored. For this purpose, at least five units will monitor
the quality of medicines and insecticides at different sites in the country.
One unit in each State will be responsible for quality assurance of diagnosis.
In addition, there will be an independent inspection agency monitoring the
quality of pharmaceuticals by testing random samples. This sub-component
will also include strengthening of laboratory work through quality assurance
for RDKs (for malaria and Kala-azar)and microscopy (for malaria) and
52